About
Overview
Leadership
Board of Directors
Science
Overview
Pipeline
SMARCA2
CDK9
Precision ADCs
CDK4/6
Discovery Engine
Publications
Clinical Trials
Overview
PRT3789 Trials
PRT2527 Trials
PRT3645 Trials
Investors
Overview
News & Events
News Releases
Events & Presentations
SMARCA Educational Video Series
Financials
SEC Filings
Quarterly Results
Stock Information
Stock Quote & Chart
Analysts
Governance
Governance Documents
Leadership
Committee Composition
Investor Resources
Investor Faqs
Contact IR
Email Alerts
News
Life at Prelude
Overview
Open Positions
Contact
About
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.
About
Overview
Leadership
Board of Directors
Science
Overview
Pipeline
SMARCA2
CDK9
Precision ADCs
CDK4/6
Discovery Engine
Publications
Clinical Trials
Overview
PRT3789 Trials
PRT2527 Trials
PRT3645 Trials
Investors
Overview
News & Events
News Releases
Events & Presentations
SMARCA Educational Video Series
Financials
SEC Filings
Quarterly Results
Stock Information
Stock Quote & Chart
Analysts
Governance
Governance Documents
Leadership
Committee Composition
Investor Resources
Investor Faqs
Contact IR
Email Alerts
News
Life at Prelude
Overview
Open Positions
Contact
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
About
Overview
Leadership
Board of Directors
Science
Overview
Pipeline
SMARCA2
CDK9
Precision ADCs
CDK4/6
Discovery Engine
Publications
Clinical Trials
Overview
PRT3789 Trials
PRT2527 Trials
PRT3645 Trials
Investors
Overview
News & Events
News Releases
Events & Presentations
SMARCA Educational Video Series
Financials
SEC Filings
Quarterly Results
Stock Information
Stock Quote & Chart
Analysts
Governance
Governance Documents
Leadership
Committee Composition
Investor Resources
Investor Faqs
Contact IR
Email Alerts
News
Life at Prelude
Overview
Open Positions
Contact
